John Hamilton, chief clinical outreach officer at Mountainside Addiction Treatment Center, discusses how benzodiazepines have not only played a dangerous role in the opioid epidemic but have actually started an epidemic of their own. Find out more on www.mountainside.com
Dr. Russell Rosenberg discusses the importance of asking patients about sleep disorders, treatment of sleep disorders and the latest data gathered from the SLEEP annual meeting (June 2018). Learn more from www.sleepfoundation.org
Returning guest Dr. Bruce Brown, M.D., discusses the importance of active surveillance in prostate cancer and Dendreon’s new ProVent trial with PROVENGE (sipuleucel-T) that aims to stop disease progression for men in early-stage prostate cancer. For more information about Provenge, visit www.dendreon.com and www.provenge.com
Dr. Tahseen Mozaffar discusses the symptoms of generalized myasthenia gravis (gMG), diagnostic challenges, prognosis, and new therapeutic options for managing gMG. Learn more at www.myasthenia.org
Nancy Law discusses the rare neurological disorder Myasthenia Gravis, the foundation’s mission, and her own journey with this condition.
Dr. Demaerschalk discusses stroke and how prompt treatment is crucial. Early action can minimize brain damage and improve outcomes. The good news is that strokes can be treated and prevented.
To mark World Vitiligo Day 2018, Dr. Phillip Artemi, one of Australia’s leading dermatologists and Director of The Vitiligo Centre Australia joins Health Professional Radio to promote greater understanding and awareness of vitiligo in order to help stem the growing trend of bullying and low self-esteem amongst sufferers.
Dr. Danny Rischin discusses an ASCO (American Society of Clinical Oncology) abstract (June 2018) he authored titled the “Primary analysis of phase 2 results for cemiplimab, a human monoclonal anti-PD-1, in patients with metastatic cutaneous squamous cell carcinoma (mCSCC)”. For more information, visit www.petermac.org
Returning guest Wendi Dumbroff, MA, LPC, discusses the use of mindfulness techniques in her practice as an innovative and added benefit for her clients.
Dr. Joshua Hare, MD, co-founder and Chief Science Officer of biotech company Longeveron, and founding director of the Interdisciplinary Stem Cell Institute at the University of Miami Miller School of Medicine, discusses two published positive clinical studies of stem cell treatment for aging frailty and how Longeveron is progressing with development of stem cell therapies for aging-related conditions to improve quality of life. www.longeveron.com